2 results match your criteria: "Paoli Hospital Cancer Center[Affiliation]"
A Case of Nivolumab-Induced Myositis.
Oncologist
December 2016
Paoli Hospital Cancer Center, Paoli, Pennsylvania, USA.
Nivolumab (Opdivo) is a monoclonal antibody classified as an immune modulator. A case is presented of nivolumab-induced myositis, an unlisted side effect.
View Article and Find Full Text PDFPostirradiation Morphea: A Case Report With a Review of the Literature and Summary of the Clinicopathologic Differential Diagnosis.
Am J Dermatopathol
October 2013
*Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA; †Department of Dermatology, University of Pennsylvania, Philadelphia, PA; and ‡Department of Radiation Therapy, Paoli Hospital Cancer Center, Paoli, PA.
: Postirradiation morphea is a rare complication of radiation therapy which often presents as an erythematous indurated plaque and may be mistaken for recurrent or metastatic carcinoma. Histologic examination is essential for distinguishing postirradiation morphea from malignant processes and from other types of radiation dermatitis and infectious cellulitis. We report a case of postirradiation morphea and review the postirradiation morphea literature.
View Article and Find Full Text PDF